ФАРМАКОКІНЕТИКА ТА ФАРМАКОДИНАМІКА АНТИМІКРОБНИХ ЛІКАРСЬКИХ ЗАСОБІВ У ПАЦІЄНТІВ З ПОРУШЕННОЮ ФУНКЦІЄЮ НИРОК: АМІНОГЛІКОЗИДИ
Анотація
Обзор фармакокинетики и фармакодинамики аминогликозидных антибиотиков у пациентов с нормальной и нарушенной функцией почек. Особое внимание уделено дозированию различных аминогликозидных антибиотиков у пациентов с разной степенью нарушения функции почек, а так же получающих лечение различными методами диализной почечной заместительной терапией.
Завантаження
Посилання
Справочник Сэнфорда по противомикробной терапии. / Гилберт Д.Н., Мѐллеринг-младш. Р.К., Элиопулос Дж.М., Чэмберс Г.Ф., Сааг М.С., // Украинский медицинский вестник. – Киев.– 2012.
Aminoglicoside antibiotics from chemical biology to drug discovery / Ed. by Dov P. Arya // John Wiley and Sons. Inc. – 2007.
Baciewicz A.M. Aminoglycoside-associated nephrotoxicity in the elderly / Baciewicz A.M., Sokos D.R., Cowan R.I. // Ann. Pharmacother. – 2003. – V.37. – P.182–186.
Barclay M.L. Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored? / Barclay M.L., Kirkpatrick C.M., Begg E.J. // Clin. Pharmacokinet. – 1999. – V.36. – P.89–98.
Blaser J. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance / Blaser J., Stone B.B., Groner M.C., Zinner S.H. // Antimicrob. Agents Chemother. – 1987. – V. – 31. – P.1054–1060.
Breilh D. Pharmacokinetics of Isepamicin during Continuous Venovenous Hemodiafiltration / Breilh D., Allaouchiche B., Jaumain H.L.N., Treau P.B., Chassard D., Malbec I., Ducint D., Saux M.-C. // Antimicrobial agents and chemotherapy. – 1999. – P.2409–2411.
Craig W.A. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections / Craig W.A., Redington J., Ebert S.C. // J. Antimicrob. Chemother. – 1991. – V.27. – P.29–40.
Craig W.A. Pharmacokinetic ⁄ pharmacodynamic parameters: rationale for antibacterial dosing of mice and men / Craig W.A. // Clin. Infect. Dis. – 1998. – V.26. – P.1–10.
Critical Care Nephrology. / C. Ronco et al. // 2nd Edition. – 2009.
Daikos G.L. Adaptive resistance to aminoglycoside antibiotics from first-exposure downregulation / Daikos G.L., Jackson G.G., Lolans V.T., Livermore D.M. // J. Infect. Dis. – 1990. – V. – 162 – P. 414–420.
Dang L. Development of a semimechanistic model to describe the pharmacokinetics of gentamicin in patients receiving hemodialysis / Dang L., Duffull S. // J. Clin. Pharmacol. – 2006. – V.46. – P.662–673.
Falagas M.E. The role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials / Falagas M.E., Matthaiou D.K., Bliziotis I.A. // J. Antimicrob. Chemother. – 2006. V.57. – P.639–647.
Gavalda J. Efficacy of ampicillin combined with ceftriaxone and gentamicin in the treatment of experimental endocarditis due to Enterococcus faecalis with no high- level resistance to aminoglycosides / Gavalda J., Onrubia P.L., Gomez M.T., et al. // J. Antimicrob. Chemother. – 2003. – V.52. – P.514–517.
Graham A.C. Extended-interval aminoglycosid dosing for treatment of enterococcal and staphylococcal osteomyelitis / Graham A.C., Mercier R.C., Achusim L.E., et al. // Ann. Pharmacother. – 2004. – V.38. – P.936–941.
Gudmundsson S. The post-antibiotic effect of antimicrobial combinations in aneutropenic murine thigh infection model / Gudmundsson S., Einarsson S., Erlendsdottir H., Moffat J., Bayer W., Craig W.A. // J. Antimicrob. Chemother. – 1993. – V.31. – P.177–191.
Kidney Disease: Improving Global Outcomes (KDIGO) / Acute Kidney Injury Work Group // KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney inter., Suppl. – 2012. – V.2. – P.1–138.
Kiel P.J. An evaluation of amikacin nephrotoxicityin the hematology/oncology population / Kiel P.J., Lo M., Stockwell D., et al. // Am. J. Ther. – 2008. – V.15. – P.131–136.
Manley H.J. Pharmacokinetics of Intermittent Intravenous Cefazolin and Tobramycin in Patients Treated with Automated Peritoneal Dialysis / Manley H.J., Bailie G.R., Frye R., Hess L.D., McGoldrick M.D. // J. Am. Soc. Nephrol. – 2000. – V.11. – P.1310–1316.
Minimum Infusion Volumes for Fluid Restricted Critically Ill Patients, / UKCPA Critical Care Group // 3rd edition. – 2006.
Mohamed O.H.K. Administration of Tobramycin in the Beginning of the Hemodialysis Session: A Novel Intradialytic Dosing Regimen / Mohamed O.H.K., Wahba I.M., Watnick S., Earle S.B., Bennett W.M., Ayres J.W., Munar M.Y. // Clin. J. Am. Soc. Nephrol. – 2007. – V.2. – P.694-699.
O’Shea S. Aminoglycosides in Hemodialysis Patients: Is the Current Practice of Post Dialysis Dosing Appropriate? / O’Shea S., Duffull S., Johnson D. W. // Seminars in Dialysis – 2009. – V. 22. – N. 3 – P. 225–230.
Peritoneal dialysis-related infections recommendations: 2005 update. / Piraino B., Bailie G.R., Bernardini J., et al. // Peritoneal Dialysis International – 2005. – V.25.
– Р. 107–131.
Peritoneal dialysis-related infections recommendations: 2010 update. / Kam-Tao Li P., Chun Szeto C., Piraino B., Bernardini J., Figueiredo A.E., Gupta A., Johnson D.W., Kuijper E.J., Lye Wai-Ch., Salzer W., Schaefer F., Struijk D.G. // Perit. Dial. Int. – 2010. – V.30. – P.393–423.
Roberts J.A. DALI: Defining Antibiotic Levels in Intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic / Roberts J.A., De Waele J.J., Dimopoulos G., Koulenti D., Martin C., Montravers P., Rello J., Rhodes A., Starr T., Wallis S.C., Lipman J. // BMC Infectious Diseases. – 2012. – V.12. – P.152.
Roberts J.A. Using Population Pharmacokinetics To Determine Gentamicin Dosing during Extended Daily Diafiltration in Critically Ill Patients with Acute Kidney Injury / Roberts J.A., Field J., Visser A., Whitbread R., Tallot M., Lipman J., Kirkpatrick C.M. J. // Antimicrobial agents and chemotherapy. – 2010. – V.54.
– N.9. – P.3635–3640.
Rybak M.J. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. / Rybak M.J., Abate B.J., Kang S.L., Ruffing M.J., Lerner S.A., Drusano G.L. // Antimicrob. Agents Chemother. – 1999. – V.43. – P.1549–1555.
Shekar K. ASAP ECMO: Antibiotic, Sedative and Analgesic Pharmacokinetics during Extracorporeal Membrane Oxygenation: a multi-centre study to optimize drug therapy during ECMO / Shekar K., Roberts J.A., Welch S., Buscher H., Rudham S., Burrows F., Ghassabian S., Wallis S.C., Levkovich B., Pellegrino V., McGuinness S., Parke R., Gilder E., Barnett A.G., Walsham J., Mullany D.V., Fung Y.L., Smith M.T., Fraser1 J.F. // BMC Anesthesiology. – 2012. – V.12. – P.29.
Sowinski K.M. Influence of Hemodialysis on Gentamicin Pharmacokinetics, Removal During Hemodialysis, and Recommended Dosing / Sowinski K.M., Magner S.J., Lucksiri A., Scott M.K., Hamburger R.J., Mueller B.A. // Clin. J. Am. Soc. Nephrol. – 2008. – V.3. – P.355–361.
The Renal Drug Handbook Third Edition / Ashley C., Currie A. // Radcliffe Publishing Ltd. – 2009.
Varghese J.M. Pharmacokinetics of Intraperitoneal Gentamicin in Peritoneal Dialysis Patients with Peritonitis (GIPD Study) / Varghese J.M., Roberts J.A., Wallis S.C., Boots R.J., Healy H., Fassett R.G., Lipman J., Ranganathan D. // Clin. J. Am. Soc. Nephrol. – 2012. – V.7. – P.1249–1256.
Yamamoto T. Proposal of a Pharmacokinetically Optimized Dosage Regimen of Antibiotics in Patients Receiving Continuous Hemodiafiltration / Yamamoto T., Yasuno N., Katada S., Hisaka A., Hanafusa N., Noiri E., Yahagi N., Fujita T., Suzuki H. // Antimicrobial agents and chemotherapy. – 2011. – V.55. – N.12. – P. 5804–5812.
Журнал розповсюджується за ліцензією 